By SIRION Biotech…
To get in touch with SIRION Biotech bringing advanced viral vector technologies to SFTCG Lyon, simply fill out the form below.
Subscribe to Supplier
SIRION Biotech bringing advanced viral vector technologies to SFTCG Lyon
Important Information: The event, which was due to take place from 11th March 2020, has been postponed.
Martinsried, Germany: – Bavarian-based viral technology specialist SIRION Biotech GmbH will return to the congress of the French Society of Cellular and Genetic Therapy (SFTCG), this year being held in Lyon.
Once again, SIRION will be looking to exchange knowledge with respected peers in the fields of biotherapies, regenerative medicine, gene transfer and cell biology, while presenting its leading capabilities in developing adeno-associated viruses (AAVs) and viral vectors.
Lentiviral transduction enhancement
The SIRION team in Lyon will be led by Dr. Francois Vromman, its Director of Sales & Business Development for France, Benelux & Italy.
“In our conversations, we will be stressing SIRION Biotech’s expertise in viral vector design optimization and our abilities to provide innovative solutions for improvement of the clinical trials that require lentiviral transduction enhancement,” said Dr. Vromman.
About SIRION Biotech
Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titres and quantities needed for preclinical human and animal testing.
Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.
SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.
Learn more at: www.sirion-biotech.com
About SFTCG 2020
The French Society of Cellular and Genetic Therapy (SFTCG) is a non-profit organization representing scientists concerned with the development of new cellular and gene therapies. The SFTCG mission is to promote therapeutic progress in the field of biotherapies, regenerative medicine, technologies based on gene transfer and cell biology for diseases of all types, genetic or acquired; for example metabolic, muscular, neurological, cardiovascular, skin, hematological, immunological diseases, cancer and infectious diseases.
The Society meets biennially, with the 2020 meeting held as a three-day event opening March 11 at the ENS congress center in Lyon.
The event is organised by SFTCG with further information at: https://www.sftcg.fr/Congrès/Lyon-2020.aspx